- Novo Nordisk (NVO) is set to initiate a Phase 2 study of oral Victoza.
- "It is a milestone because this is not incremental innovation, it's disruptive innovation," CSO Mads Krogsgaard Thomsen tells Reuters.
- Although developing an oral formulation of the $1.7B-selling GLP-1 diabetes treatment won't be easy, Thomsen says "the data [he has] so far suggests [NVO] can do it."
- NVO is looking to get the oral version to market within five to six years, Reuters says.
- NVO +3.9% premarket
Novo Nordisk to start Phase 2 study of diabetes pill
Nov 29 2013, 08:58 ET